Clinical Trial Update: Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan [Phase 2]

View source ↗

Summary

Phase II study of lenalidomide/dexamethasone with or without elotuzumab in newly diagnosed multiple myeloma patients in Japan completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide Dexamethasone with Elotuzumab

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2018-03-22